Cardiometabolic properties of telmisartan: new perspectives for use
https://doi.org/10.20996/1819-6446-2015-11-6-650-654
Abstract
Modern clinical studies periodically open new prospects for the use of well-known products, lighting other facets of the point of application of these drugs. Application of the last representatives of sartans, not only as a drug with proven antihypertensive effect, but also in terms of their effects on metabolic processes, can be considered as such an example.
About the Authors
O. M. Drapkina
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Russian Federation
E. I. Fomicheva
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Russian Federation
References
1. Boytsov SA, Jakushin SS Martsevich SY, et al. Register outpatient cardiovascular disease REKVAZA. Ration Pharmacother Cardiol 2013; 9 (1): 4-14. In Russian (Бойцов С.А., Якушин С.С., Марцевич С.Ю., и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний РЕКВАЗА. Рациональная Фармакотерапия в Кардиологии 2013; 9 (1): 4-14).
2. Diagnosis and treatment of hypertension. Russian guidelines (fourth revision). Sistemnye Gipertenzii 2010; 3: 3-25. In Russian (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные Гипертензии 2010; 3: 3-25).
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
4. Schmieder R, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351-1356.
5. Bakris G., Burgess E., Weir M. et al.; on behalf of the AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74 (3): 364.
6. Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174-83.
7. MakinoH, Haneda M, Babazono T, et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy - rationale, study design, treatment plan and baseline characteristics of the incipientto overt: angiotensin iireceptor blocker,telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677-86.
8. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
9. Miura S, Karnia SS, Saku K. Review: angiotensin II type I receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12 (1): 1-7.
10. Mori H, Okada Y, Arao T, et al. Telmisartan at 80 mg/day increases higt-molecular-weight adiponectin levels and improves insulinresistance in diabetic patients. Adv Ther 2012; 29 (7): 635-44.
11. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43(5):993-1002.
12. Schupp M, Clemenz M, Gineste R et al. Molecular characterization of new selective peroxisome proliferator-activated receptor c modulators with angiotensin receptor blocker activity. Diabetes, 2005; 54: 3442-52.
13. Hara K, Horikoshi M, Yamauchi T et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 2006; 29: 1357-62.
14. Lara-Castro C, Luo N, Wallace P, et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 2006; 55: 249-59.
15. Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J of Clinical Pharmacy and Therapeutics 2012; 37:3; 319-27.
16. Kurtz T W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferatoractivated receptorgamma activator. Acta Diabetologica, 2005; 2005:42.
17. Francischetti E A, Celoria B M, Francischetti A, Genelhu V A. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Review of Cardiovascular Therapy 2008; 6: 280-303.
18. Takagi H, Niwa M, Mizuno Y, Umemoto T. Telmisartan as a metabolic sartan: The first meta-analysis of randomized controlled trials in metabolic syndrome. J of the American Society of Hypertension 2013; 7:3; 229-35.
19. Derosa G, Cicero AF, D’Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29: 849-56.
20. Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007; 46: 1331-6.
21. Kishi T, Hirooka Y, Konno S, Sunagawa K. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens 2012; 30:1646-55.
22. Blüher M, Brennan AM, Kelesidis T, et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007; 30:280-5.
23. Mori H, Okada Y, Arao T, Nishida K, Tanaka Y. Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients. Original research. Advances in Therapy 2012; 29:7 635-44.
24. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003; 9:406-16.
Review
For citations:
Drapkina O.M., Fomicheva E.I. Cardiometabolic properties of telmisartan: new perspectives for use. Rational Pharmacotherapy in Cardiology. 2015;11(6):650-654. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-6-650-654
Views:
986
Email this article 